Guangdong Zhongsheng Raynovent Biotechnology

Raynovent is a China-based biopharmaceutical company specializing in the discovery and development of innovative small molecule drugs for infectious diseases and respiratory disorders. As a subsidiary of Guangdong Zhongsheng Pharmaceutical, the company has successfully transitioned from R&D to commercialization with the approval of Leritrelvir, an oral 3CL protease inhibitor for COVID-19. Its robust pipeline includes Onradivir, a late-stage candidate for Influenza A, alongside several programs targeting non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis. Raynovent focuses on addressing significant unmet medical needs in the Chinese market through internal innovation and strategic partnerships. The company leverages its parent organization's extensive manufacturing and commercial infrastructure to accelerate the delivery of novel therapies.